৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Indications
Vintelix is indicated for the treatment of major depressive disorder [MDD] in adults.
Pharmacology
The mechanism of the antidepressant effect of Vortioxetine is not fully understood, but it is thought to be related to its enhancement of serotonergie activity in the central nervous system through inhibition of
the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
Dosage & Administration
Recommended dose: The recommended starting dose is 10 mg administered orally once daily without regard to meals. The dosage should then be increased to 20 mg/day, as tolerated. The efficacy and safety of
doses above 20 mg/day have not been evaluated in controlled clinical trials. A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses. The lowest effective dose of 5
mg/day should always be used as the starting dose for elderly patients (>65 yoars of aga).
Maintenance dose: For MDD, Vortioxetine can be administered for several months or longer. For a long period use patients should be re-evaluated to assess the usefulness of the drugs for individual patients.
Discontinuation treatment: Although Vortioxetine can be abruptly discontinued, in placebo-controlled trials patients axperienced transient adverse reactions such as headache and muscle tension following
abrupt discontinuation of Vortioxetine 15 mg/day or 20 mg/day. To avoid these adverse reactions, it is recommended that the dose should be decreased to 10 mg/day for one week before full discontinuation of
Vortioxetine 15 mg/day or 20 mg/day.
Switching a patient to or from a Monoamine Oxidase Inhibitor (MAOI) intended to treat Psychiatric Disorders: At least 14 days must elapse between discontinuation of an MAD intended to treat psychiatrie
disorders and initiation of therapy with Vortioxetine to avoid the risk of Serotonin Syndrome. Conversely, at least 21 days must elapse after stopping Vortioxetine betore starting an MADI intended to treat
psychiatric disorders.
Interaction
Monoamine Oxidase Inhibitors: Adverse mactions, some of which are serious or fatal, can develop in patients who use MAOls or who have recently been discontinued from an MAOI and started on a serotonergie
antidepressant(s) or who have recently had SSRI or SNRI therapy discontinued prior to initiation of an MADL
Serotonergie drugs: Co-administration of Vintelix with other drugs that may affect the serotonergie neurotransmitter systems [e.g. SSRIs, SNRIs, Triptans, Buspirone, Tramadol, and Tryptophan products ete.)
may potentially increase serotonin taxicity or serotonin syndrome. Closely monitor symptoms of serotonin syndrome it Vintelie is co-administered with other serotonergic drugs. Treatment with Vintelie and any
concomitant serotonergie agents should be discontinued immediately if serotonin syndrome occurs.
Other CNS active agents: No clinically relevant effect was observed on steady-state Lithium axposure following co-administration with multiple daily doses of Vintelix.
Potential for other drugs to affeet Vintelix: Reduce Vintelix dose by halt when a strong CYP206 inhibitor (e.g. Bupropion, Fuoxetine, Paroxatine, Quinidine) is co-administered. Consider inoreasing the Vintelix
dose when a strong CYP inducer(e.g. Rifampin, Carbamazepine, Phenytoin) is co-administerad.
Contraindications
Vortioxetine Hydrobromide is contraindicated in Patients with known hypersensitivity to Vortioxetine or any of the excipients of the drug product & concomitant use of Monoamine Dddase Inhibitors [MAOIs].
Side Effects
Patients taking Vintelix may experience some adverse events such as Hypersensitivity, Clinical worsening and suicide risk, Serotonin syndrome, Abnormal bleeding, activation of Mania/Hypomania, Angle closure
Glaucoma, Hyponatremia.
Pregnancy & Lactation
The satety of Vortioxstine in human pregnancy has not been established. Therefore, Vorticostine should not be used during pregnancy or in women intending to become pregnant, unless the benefits outweigh
the possible risks to the fetus. Avallable data in animals have shown the excretion of Vortioxetine metabolites in milk. It is expected that Vortioxstine will be excreted into human milk. Because risks to the nursing
child cannot be excluded, breastfeeding is not recommended during treatment with Vortioxetine.
Precautions & Warnings
Clinical Worsening and Suicide Risk: All patients being treated with antidepressants for anyindication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusuall
changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, elther increases or decreases.
Serotonin Syndrome: The development of a potentially lfe-threatening serotonin syndrome has been reported with serotonergie antidepressants including Vintelix, when used alone but more often when used
concomitantly with other serotonergie drugs (including Triptans, Tricyclic Antidepressants, Fentanyl, Lithium, Tramadol, Tryptophan, Buspirone & St. John's Wort), and with drugs that impair metabolism of
serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as Linezolid and intravenous methylene blua).
Abnormal Bleeding: The use of drugs that interfere with serotonin reuptake inhibition, including Vintelix, may increase the risk of bleeding events. Concomitant use of Aspirin, Nonsteroidal
Anti-inflammatory drugs [NSAIDs), Wartarin, and other Anticoagulants may add to this risk. Activation of
Mania/Hypomania: As with all Antidepressants, use Vintelix cautiously in patients with a history or family history of bipolar disorder, mania, or hypomania.
Angle Closure Glaucoma: The pupillary dilation that occurs following the use of many Antidepressant drugs, including Vinteli, may trigger an angle closure attack in a patient with anatomically narrow angles
who does not have a patent iridectomy.
Hyponatremia: Hyponatremia occurrs because of treatmant with serotonergie drugs.
Use in Special Populations
Pediatric use (<18 years of age): The safety and effectiveness of Vintelix in the pediatrie population have not been established.
Geriatries use [>65 years of age): No dose adjustment is recommended on the basis of age. Results from a single-dose pharmacokinetie study in elderly (>65 years old) vs young (24 to 45 years old) subjects
demonstrated that the pharmacokineties were gonerally similar between the two age groups.
Renal impairment: No dose adjustment is needed.
Hepatie impairment: No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Vintelix is not recommended in patients with severe hepatic impairment.
CYP206 poor metabolizers: The plasma concentration of Vintelix was approximately two times higher in CYP206 poor metabolizers than in extensive metabolizers. In the presence of strong CYP3A4/2C9
inhibitors, the exposure could potentially be higher, and a dosage adjustment may be required.
Use in other patient populations: No dose adjustment of Vintelix is needed on the basis of race, gender and ethnicity.
Overdose Effects
There is limited data avallable on Vintelix overdose. Medical follow-up in a specialized environment is recommended.
Therapeutic Class
Serotonin-norepinaphrine rouptake inhibitor (SNR()
Storage Conditions
Store at 30℃ or below in a dry place. Keep away from light. Keep out of the reach of the children.





Vortioxetine Hydrobromide is a prescription antidepressant used to treat major depressive disorder (MDD). It works by modulating serotonin activity in the brain—blocking and stimulating different serotonin receptors while also inhibiting serotonin reuptake.
Vortioxetine is used for depression, low mood, lack of interest, anxiety symptoms associated with depression, and cognitive symptoms like poor concentration. It may improve mood, energy, and mental clarity.





